Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: Analysis of 1002 patients from the EUSCLE database

British Journal of Dermatology

Volumn 171, Issue 3, 2014, Pages 571-579

  Kuhn, A ^a,b   Sigges, J ^b   Biazar, C ^b   Ruland, V ^b   Patsinakidis, N ^b   Landmann, A ^a   Amler, S ^b   Bonsmann, G ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; HYDROXYCHLOROQUINE; MEPACRINE; SUNSCREEN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CHILD; CORE SET QUESTIONNAIRE OF THE EUROPEAN SOCIETY OF CUTANEOUS LUPUS ERYTHEMATOSUS; CROSS-SECTIONAL STUDY; CUTANEOUS LUPUS ERYTHEMATOSUS DISEASE AREA AND SEVERITY INDEX; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEWBORN; PRIORITY JOURNAL; SKIN DISEASE ASSESSMENT; SKIN LUPUS ERYTHEMATOSUS; SMOKING; VERY ELDERLY; ADVERSE EFFECTS; CLINICAL TRIAL; LUPUS ERYTHEMATOSUS, CUTANEOUS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMALARIALS; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SMOKING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925248644     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13006     Document Type: Article

References (43)

1. Kuhn A, Kuehn E, Meuth AM, et al,. Development of a core set questionnaire for the evaluation of cutaneous lupus erythematosus. Autoimmun Rev 2009; 8: 702-12.
2. Kuhn A, Patsinakidis N, Bonsmann G,. The impact of the EUSCLE Core Set Questionnaire for the assessment of cutaneous lupus erythematosus. Lupus 2010; 19: 1144-52.
3. Albrecht J, Taylor L, Berlin JA, et al,. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005; 125: 889-94.
4. Meuth AM, Amler S, Haust M, et al,. A database analysis of cutaneous lupus erythematosus with the EUSCLE Core Set Questionnaire. Acta Derm Venereol 2010; 90: 386-94.
5. Bein D, Kuehn E, Meuth A, et al,. Evaluation of disease activity and damage in different subtypes of cutaneous lupus erythematosus using the CLASI. J Eur Acad Dermatol Venereol 2011; 25: 652-9.
6. Gallego H, Crutchfield CE 3rd, Lewis EJ, et al,. Report of an association between discoid lupus erythematosus and smoking. Cutis 1999; 63: 231-4.
7. Miot HA, Bartoli Miot LD, Haddad GR,. Association between discoid lupus erythematosus and cigarette smoking. Dermatology 2005; 211: 118-22.
8. Rahman P, Gladman DD, Urowitz MB,. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 1998; 25: 1716-19.
9. Jewell ML, McCauliffe DP,. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000; 42: 983-7.
10. Kreuter A, Gaifullina R, Tigges C, et al,. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Arch Dermatol 2009; 145: 244-8.
11. Polet H,. The effects of lysosomotropic amines on protein degradation, migration of nonhistone proteins to the nucleus, and cathepsin D in lymphocytes. J Cell Physiol 1985; 122: 415-23.
12. Kuhn A, Ochsendorf F, Bonsmann G,. Treatment of cutaneous lupus erythematosus. Lupus 2010; 19: 1125-36.
13. Kuhn A, Ruzicka T,. Classification of cutaneous lupus erythematosus. In: Cutaneous Lupus Erythematosus. (, Kuhn A, Lehmann P, Ruzicka TS, eds), Heidelberg: Springer, 2004, 53-8.
14. Sciascia S, Bertolaccini ML, Baldovino S, et al,. Central nervous system involvement in systemic lupus erythematosus: overview on classification criteria. Autoimmun Rev 2013; 12: 426-9.
15. Borchers AT, Leibushor N, Naguwa SM, et al,. Lupus nephritis: a critical review. Autoimmun Rev 2012; 12: 174-94.
16. Klein R, Moghadam-Kia S, LoMonico J, et al,. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol 2011; 147: 203-8.
17. Sigges J, Biazar C, Landmann A, et al,. Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus. Autoimmun Rev 2013; 12: 694-702.
18. Biazar C, Sigges J, Patsinakidis N, et al,. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 2012; 12: 444-54.
19. Metelitsa AI, Lauzon GJ,. Tobacco and the skin. Clin Dermatol 2010; 28: 384-90.
20. La Torre G, Kirch W, Bes-Rastrollo M, et al,. Tobacco use among medical students in Europe: results of a multicentre study using the Global Health Professions Student Survey. Public Health 2012; 126: 159-64.
21. Boeckler P, Cosnes A, Frances C, et al,. Association of cigarette smoking but not alcohol consumption with cutaneous lupus erythematosus. Arch Dermatol 2009; 145: 1012-16.
22. Boeckler P, Milea M, Meyer A, et al,. The combination of complement deficiency and cigarette smoking as risk factor for cutaneous lupus erythematosus in men; a focus on combined C2/C4 deficiency. Br J Dermatol 2005; 152: 265-70.
23. Piette EW, Foering KP, Chang AY, et al,. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol 2012; 148: 317-22.
24. Turchin I, Bernatsky S, Clarke AE, et al,. Cigarette smoking and cutaneous damage in systemic lupus erythematosus. J Rheumatol 2009; 36: 2691-3.
25. Kuhn A, Sontheimer RD,. Cutaneous lupus erythematosus: molecular and cellular basis of clinical findings. Curr Dir Autoimmun 2008; 10: 119-40.
26. Kuhn A, Bein D, Bonsmann G,. The 100th anniversary of lupus erythematosus tumidus. Autoimmun Rev 2009; 8: 441-8.
27. Kuhn A, Richter-Hintz D, Oslislo C, et al,. Lupus erythematosus tumidus-a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 2000; 136: 1033-41.
28. Schmitt V, Meuth AM, Amler S, et al,. Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus. Br J Dermatol 2010; 162: 64-73.
29. Albrecht J, Werth VP,. Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus. Dermatol Ther 2007; 20: 93-101.
30. Bonilla-Martinez ZL, Albrecht J, Troxel AB, et al,. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol 2008; 144: 173-80.
31. Kuhn A, Meuth AM, Bein D, et al,. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol 2010; 163: 83-92.
32. Wahie S, Daly AK, Cordell HJ, et al,. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol 2011; 131: 1981-6.
33. Lardet D, Martin S, Truchetet F, et al,. Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study. Rev Med Interne 2004; 25: 786-91.
34. Leroux G, Costedoat-Chalumeau N, Hulot JS, et al,. Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases. Ann Rheum Dis 2007; 66: 1547-8.
35. Dutz J, Werth VP,. Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma. J Invest Dermatol 2011; 131: 1968-70.
36. Ochsendorf FR,. Use of antimalarials in dermatology. J Dtsch Dermatol Ges 2010; 8: 829-44.
37. Kuhn A, Ruland V, Bonsmann G,. Cutaneous lupus erythematosus: update of therapeutic options Part I. J Am Acad Dermatol 2011; 65: e179-93.
38. Wallace DJ,. Is there a role for quinacrine (Atabrine) in the new millennium? Lupus 2000; 9: 81-2.
39. Wallace DJ,. The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum 1989; 18: 282-96.
40. Chang AY, Piette EW, Foering KP, et al,. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol 2011; 147: 1261-7.
41. Chung HS, Hann SK,. Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine. J Dermatol 1997; 24: 569-72.
42. Feldmann R, Salomon D, Saurat JH,. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 1994; 189: 425-7.
43. von Schmiedeberg S, Ronnau AC, Schuppe HC, et al,. [Combination of antimalarial drugs mepacrine and chloroquine in therapy refractory cutaneous lupus erythematosus]. Hautarzt 2000; 51: 82-5 (in German).